Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC) - Motzer, R J; Choueiri, T K; McDermott, D F (Journal of Clinical Oncology, 2020)
et al.